Dendritic Cell Vaccination in Treatment of Relapsed Pediatric AML
2 विचारों
• 07/04/23
0
0
एम्बेड
administrator
ग्राहकों
Despite allogeneic hematopoietic cell transplantation the survival chances in pediatric AML are 50% only. With the developed adjuvant WT1 Cord Blood Derived Dendritic Cell Vaccine the survival chances may increase. The clinical study will start early 2017.
PIs: Dr Jaap Jan Boelens (clinical / translational) and Dr Stefan Nierkens (lab / translational)
और दिखाओ
फेसबुक टिप्पणियाँ
SORT BY-
सबसे ऊपर की टिप्पणी
-
नवीनतम टिप्पणियां